The CMS dropped a Trump-era rule that would have tied Medicare prices for some outpatient drugs to the lowest prices paid by other wealthy countries, citing procedural issues with how it was initially put in place. The rule, known as the most favored national policy, faced opposition from the drug industry and some Republicans and eventually got bogged down in legal challenges. (Article here)